The present invention relates to a new use for compounds having 5-HT.sub.3 (serotonin M) receptor antagonist activity, especially tropisetron, for the manufacture of a pharmaceutical composition for the systemic treatment of an inflammatory rheumatic or rheumatoid disease other than crystal induced arthritis and other than living pathogen induced inflammatory diseases as long as the living pathogen is still present.

Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes

The present invention relates to a new use for compounds having 5-HT.sub.3 (serotonin M) receptor antagonist activity, especially tropisetron, for the manufacture of a pharmaceutical composition for the treatment of a non-inflammatory local disease of the musculo-sceletal system, of a local irritation condition of a joint or tendon sheath, or for the local treatment a local manifestation at the locomotor apparatus of an inflammatory disease except for a crystal induced arthritis and a living pathogen induced inflammatory disease condition as long as the living pathogen is still present.

Novasearch AG

Use of 5-HT.sub.3 receptor antagonists for treating musculoskeletal diseases

crystal arthropathies/seratonin

Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes

Use of 5-HT.sub.3 receptor antagonists for treating musculoskeletal diseases

Use of 5-HT3 receptor antagonists for treating musculoeskeletal diseases

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası